Oryzon Genomics S.A.

Biopharma Acquisitions Biopharma merger and acquisition value for the fourth quarter of 2022 reached $35.7bn from 41 transactions, 21 of which had disclosed values. Making up 78% of the Q4 total was A

Merck & Co., Inc. is well aware that it needs to begin planning for its post-Keytruda future, with the blockbuster anti-PD-1 agent slated to lose patent protection in 2028, but with its plans for a l

Germany’s BI Licenses Tumor-Specific Antibodies From Singapore Lab Boehringer Ingelheim GmbH and Singapore’s Agency for Science, Technology and Research (A*STAR) unveiled a global licensing agreem

Aside from disappointment for some investors that an acquirer hasn't surfaced to buy Amarin Corp. PLC – developer and marketer of the prescription-grade purified fish oil pill Vascepa (icosapent eth